US generic drugs bill seeks to fix unintended consequence of legislation, say lawmakers
This article was originally published in SRA
Executive Summary
US lawmakers have introduced a bill that seeks to temporarily double to 60 months the length of time in which a generic drug can receive US Food and Drug Administration approval and still be eligible to receive 180 days of market exclusivity on approval1,2.